FDA-Regulated Products

Overview

Like the agency itself, we have dedicated, interdisciplinary practices focusing on each segment of the Food and Drug Administration (FDA) and the Federal Food, Drug and Cosmetic Act (FDCA). We partner with stakeholders in the food, pharmaceutical, health and life sciences, and other affected industries to navigate FDA regulations and agency interactions. Companies, patient organizations and other stakeholders rely on us to provide experienced advice to help them meet regulatory expectations and navigate the FDA when they’re working with new drugs, biologics, and medical devices and related biotechnology or innovative food products and cosmetics.

Drugs and Medical Devices

As a drug and medical device innovator, patient organization or other stakeholder in the drug or device approval process, your success relies on your ability to comply with a complex framework of regulations related to research and development, marketing authorization and post-marketing compliance. We support you throughout the life cycle of a medical product — from the early research stages to the clinic, to Agency submission and approval, and on to post-marketing commitments and ongoing safety monitoring. 

Our experienced team includes attorneys with extensive experience.  Team members have worked on issues before the FDA’s Center for Drug Evaluation and Research including drug and biologics policy matters before the Office of Pharmaceutical Quality and compliance matters (including 483 responses and warning letters) before the Office of Compliance. The team leverages an interdisciplinary bench of attorneys, consultants and scientists to provide you with insight and practical advice. We handle matters including:

  • Clinical trial contracting
  • Research compliance
  • Product development strategy and early agency interactions
  • Patient-focused drug development (including patient advocacy group collaborations)
  • Software as a medical device
  • Current good manufacturing practice (CGMP) and quality system regulations and expectations
  • Laboratory audits
  • Agency determinations (i.e., INDs, IDEs and expanded access)
  • Risk evaluations and mitigation strategies (REMS)
  • Promotional communications and advertising
  • Privacy protection policies and enforcement
  • Post-marketing surveillance

We also support clients as they innovate using advanced manufacturing techniques and platform technologies, artificial intelligence (AI), machine learning (ML), and other software-based technologies.  

Food and Dietary Supplements

Leading food and dietary supplement companies confront critical legal, regulatory and business challenges every day. We help you develop and execute strategies related to the science, economics, markets, government regulation and public relations aspects of the farm to-table cycle. When disputes, regulatory changes, product recalls or legal suits emerge, our regulatory and litigation teams provide peace of mind as you implement new compliance protocols or tackle high-stakes litigation.

Cosmetics

Makers of cosmetics and personal care products must continuously adapt and expand product offerings to reflect the growing desire of consumers to express their beauty and individuality. At the same time, oversight has never been greater, as we watch FDA implement federal legislation to modernize cosmetics regulation. Creative marketing and advertising of these products may fall outside legal parameters and result in enforcement action by regulatory agencies. States have become increasingly involved in cosmetic regulation as it relates to product ingredients and consumer health. We work with you to meet these emerging challenges head-on. We review product ingredients, help navigate registration requirements and advise on prospective advertising and labeling claims that are the basis for legal challenges by regulators and competitors.

Animal Health

Companies making new animal drugs, medicated feeds and feed additives as well as pet food and animal feed need in-depth knowledge to identify applicable regulations and implement efficient development, manufacturing and marketing of animal food and drugs. We guide clients through interactions with the FDA and the United States Department of Agriculture by delivering industry insight and practical advice on complex legal issues related to adverse event reporting, recalls, criminal investigations and product liability.

Insights & Events

Latest

最新 November 2025

SCOTUS Weighs Trump Administration’s Tariff Authority Under IEEPA; Pharma and Device AI; and More

Biopharma & Medical Devices Briefing
7 min read
Speaking Engagement Recap November 07, 2025

Data, Dangers, & Developments in Drug Supply Chain Security & Safety

American Society for Pharmacy Law: 2025 Developments in Pharmacy Law
1 min read
最新 October 2025

California’s Frontier Artificial Intelligence Act & More Developments

Artificial Intelligence Briefing
7 min read
媒体报道 October 2025

Libby Baney Comments on Uncertainty in Prescription Drug Market With the Washington Post

1 min read
最新 October 2025

FDA Launches Dashboard to Provide Access to Real-Time Adverse Event Data for Cosmetics

How Users Might Get the Most Out of This Version
3 min read
最新 October 2025

FDA Requests Public Comment on Metrics and Methods for Evaluating Performance of AI-Driven Medical Devices Deployed in Clinical Settings

Written Responses Due by December 1, 2025
3 min read
最新 October 2025

FDA’s Prioritization Pilot Providing Faster Review When Generic Drugs — APIs or Finished Products — Are Produced Domestically

Could Adjusting Your Supply Chains Allow You to Take Advantage of ANDA Review Prioritization?
3 min read
Speaking Engagement Recap September 01, 2025

Better Together Starts With Being Whole Alone

The HX Experience Podcast
1 min read
Press Release May 2025

Faegre Drinker Welcomes Former Senate HELP Committee General Counsel Barrett Tenbarge to Government and Regulatory Group

3 min read
Press Release April 2025

Faegre Drinker Welcomes Life Sciences Litigator Tom Pack to California Product Liability & Mass Torts Team

3 min read
Insights
最新 November 2025

SCOTUS Weighs Trump Administration’s Tariff Authority Under IEEPA; Pharma and Device AI; and More

Biopharma & Medical Devices Briefing
7 min read
最新 October 2025

California’s Frontier Artificial Intelligence Act & More Developments

Artificial Intelligence Briefing
7 min read
媒体报道 October 2025

Libby Baney Comments on Uncertainty in Prescription Drug Market With the Washington Post

1 min read
最新 October 2025

FDA Launches Dashboard to Provide Access to Real-Time Adverse Event Data for Cosmetics

How Users Might Get the Most Out of This Version
3 min read
最新 October 2025

FDA Requests Public Comment on Metrics and Methods for Evaluating Performance of AI-Driven Medical Devices Deployed in Clinical Settings

Written Responses Due by December 1, 2025
3 min read
最新 October 2025

FDA’s Prioritization Pilot Providing Faster Review When Generic Drugs — APIs or Finished Products — Are Produced Domestically

Could Adjusting Your Supply Chains Allow You to Take Advantage of ANDA Review Prioritization?
3 min read
最新 August 2025

Effects of the One Big Beautiful Bill Act on Health Care and Pharma; and More

Biopharma & Medical Devices Briefing
7 min read
最新 July 2025

FDA Joins the Data Security Program Conversation: The Agency’s Scrutiny of Cross-Border Clinical Trials & 28 C.F.R. Part 202 Exemptions

FDA Contends Some Clinical Trials May Have Exposed Americans’ Sensitive Genetic Data to Misuse by Foreign Governments
6 min read
媒体报道 June 2025

Bench & Bar of Minnesota Highlights New MSBA President Tom Pack’s Approach to Leadership

1 min read
最新 June 2025

Supreme Court Decides Food and Drug Administration v. R.J. Reynolds Vapor Co.

3 min read

Meet The Team

Meet The Team